Trending...
- California: Governor Newsom announces appointments 9.10.25 - 270
- John Thomas calls for unity and prayer after tragic loss - 244
- Ayurveda, Ayurvedic medical Science and Ayurvedic Therapies, Dr.Abhay Kumar Pati - 236
MENLO PARK, Calif., Oct. 26, 2020 /PRNewswire/ -- Drawbridge Health, a healthcare technology company redefining the blood draw experience for both patients and healthcare providers, today announced a further investment from Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon Pharma") as well as a new research and development collaboration agreement. Drawbridge Health also reported that it has secured a strategic investment from new investor TOHO HOLDINGS CO., LTD. ("TOHO HOLDINGS"), in addition to a follow-on investment from Kyoto University Innovation Capital ("KYOTO-iCAP"). The investments will fuel Drawbridge Health's expansion in the Japanese market and support adoption of the company's innovative blood collection technology, the OneDraw™ Blood Collection Device.
The collaboration between Drawbridge Health and Sumitomo Dainippon Pharma will focus initially on the development of a biomarker panel for lifestyle-related diseases such as diabetes and diabetic complications. "Our research and development collaboration with Drawbridge Health has been undertaken to address the significant concern in Japan around lifestyle-related diseases by embracing OneDraw as a novel, transformative innovation" said Hiroyuki Baba, Senior Executive Officer at Sumitomo Dainippon Pharma.
More on The Californer
Professor Nobuya Inagaki, M.D., Ph.D., Chairman of the Department of Diabetes, Endocrinology and Nutrition at Kyoto University further highlighted the significance of the collaboration between Drawbridge Health and Sumitomo Dainippon Pharma. "This collaboration is forward-thinking, as it will help advance much-needed initiatives, resources and support the expansion of telemedicine in the Japanese medical field, particularly for lifestyle-related diseases."
"There is tremendous potential for changing the trajectory of diabetes and lifestyle disease in Japan with the OneDraw device. We are excited to partner with Drawbridge Health to improve
the health of millions," said Mr. Atsushi Udoh, President and Representative Director,
TOHO HOLDINGS.
"Globally, 2020 has proven that healthcare systems must quickly adapt to unexpected and ongoing challenges. Access to health information is more important than ever, and we appreciate the commitments from Sumitomo Dainippon Pharma and TOHO HOLDINGS as we continue our growth and vision in Japan. We also continue to be extremely grateful for the ongoing collaboration and relationship with Kyoto University and KYOTO-iCAP," said Lee McCracken, CEO of Drawbridge Health.
Drawbridge Health is committed to improving healthcare globally through more accessible blood sampling, beginning with the 2019 FDA-cleared and 2020 CE-marked OneDraw A1C Test System. OneDraw is a small, single use device that draws, collects, and stabilizes a capillary blood sample from the upper arm. This novel device is easy to use and enables blood to be drawn comfortably and conveniently without the need to visit a lab.
More on The Californer
About Drawbridge Health
Founded in 2015 by GE Ventures and GE Healthcare, Drawbridge Health is a healthcare technology company focused on reinventing the blood draw experience, enabling comfortable convenient blood sample collection anytime and anywhere. By integrating engineering, chemistries, and modular design, Drawbridge Health has developed a people-friendly system for collecting and stabilizing blood samples, opening new doors to enable access to important health information. For more information, please visit www.drawbridgehealth.com.
Contact:
Eddy Garcia
[email protected]
Learn more about the investors:
Sumitomo Dainippon Pharma
TOHO HOLDINGS CO., LTD.
KYOTO-iCAP
SOURCE Drawbridge Health
Related Links
http://www.drawbridgehealth.com
The collaboration between Drawbridge Health and Sumitomo Dainippon Pharma will focus initially on the development of a biomarker panel for lifestyle-related diseases such as diabetes and diabetic complications. "Our research and development collaboration with Drawbridge Health has been undertaken to address the significant concern in Japan around lifestyle-related diseases by embracing OneDraw as a novel, transformative innovation" said Hiroyuki Baba, Senior Executive Officer at Sumitomo Dainippon Pharma.
More on The Californer
- Global biotech leaders Amgen and Gilead announcing expansions in California, the #1 state for life sciences
- California: Governor Newsom proclaims Latino Heritage Month
- MEDIA ALERT: Cisco's WebexOne Event Spotlights Global AI Brands and Ryan Reynolds, Acclaimed Actor, Film Producer, and Entrepreneur
- Patrick Perez Steps Beyond Crunchyroll to Shape the Next Wave of Streaming & Media Innovation
- Mesa West Capital Originates $43.5 Million Loan to Refi LA Area Apartment Community
Professor Nobuya Inagaki, M.D., Ph.D., Chairman of the Department of Diabetes, Endocrinology and Nutrition at Kyoto University further highlighted the significance of the collaboration between Drawbridge Health and Sumitomo Dainippon Pharma. "This collaboration is forward-thinking, as it will help advance much-needed initiatives, resources and support the expansion of telemedicine in the Japanese medical field, particularly for lifestyle-related diseases."
"There is tremendous potential for changing the trajectory of diabetes and lifestyle disease in Japan with the OneDraw device. We are excited to partner with Drawbridge Health to improve
the health of millions," said Mr. Atsushi Udoh, President and Representative Director,
TOHO HOLDINGS.
"Globally, 2020 has proven that healthcare systems must quickly adapt to unexpected and ongoing challenges. Access to health information is more important than ever, and we appreciate the commitments from Sumitomo Dainippon Pharma and TOHO HOLDINGS as we continue our growth and vision in Japan. We also continue to be extremely grateful for the ongoing collaboration and relationship with Kyoto University and KYOTO-iCAP," said Lee McCracken, CEO of Drawbridge Health.
Drawbridge Health is committed to improving healthcare globally through more accessible blood sampling, beginning with the 2019 FDA-cleared and 2020 CE-marked OneDraw A1C Test System. OneDraw is a small, single use device that draws, collects, and stabilizes a capillary blood sample from the upper arm. This novel device is easy to use and enables blood to be drawn comfortably and conveniently without the need to visit a lab.
More on The Californer
- 10xLaw.com Extends Employment Opportunity to Kim Kardashian
- DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies
- CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
- Pacsun Announces Industry First Pacsun Youth Advisory Council: Empowering Its Consumers as Co-Creators in Brand Strategy
- Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
About Drawbridge Health
Founded in 2015 by GE Ventures and GE Healthcare, Drawbridge Health is a healthcare technology company focused on reinventing the blood draw experience, enabling comfortable convenient blood sample collection anytime and anywhere. By integrating engineering, chemistries, and modular design, Drawbridge Health has developed a people-friendly system for collecting and stabilizing blood samples, opening new doors to enable access to important health information. For more information, please visit www.drawbridgehealth.com.
Contact:
Eddy Garcia
[email protected]
Learn more about the investors:
Sumitomo Dainippon Pharma
TOHO HOLDINGS CO., LTD.
KYOTO-iCAP
SOURCE Drawbridge Health
Related Links
http://www.drawbridgehealth.com
Filed Under: Business
0 Comments
Latest on The Californer
- Car Wash Deal in Downey CA Prices Starting from $8
- Dr. Vincent Malfitano Elected to Central Council of The Italian Catholic Federation, National Gov
- Your Body Isn't Broken—It's Out of Balance: The New Book Revealing the Blueprint to Restore Hormone Balance, Sleep, Gut & Metabolic Health
- Long Beach Recognizes September as National Preparedness Month, Relaunches Program to Connect Neighborhoods to Disaster Planning Resources
- SEEAG Adds Santa Barbara County Office, Student & Community Agriculture Learning Programs
- California claims victory – again – over Huntington Beach as appeals court rules against city's NIMBY violations of state law
- The Great Junk Hunt Returns to Roseville – A Vintage Shopping Adventure Awaits!
- Erdos Technologies CEO Dan Herbatschek Emphasizes the Importance of Software in Helping Companies Make More Intelligent Decisions on Inventory Flow and Management
- MyNamePlayer Empowers Educators to Create Inclusive Classrooms Through Correct Name Pronunciation
- Long Beach Seeks Volunteers for 41st Annual California Coastal Cleanup Day, September 20
- Youth Take the Lead: Kopp Foundation for Diabetes Hosts "By Youth, For Youth, With T1D" Gala on October 8 at Blue Bell Country Club
- Wise Business Plans Launches Business Plan Writing Services in San Diego to Propel Entrepreneurs
- Green Office Partner Named #1 Best Place to Work in Chicago by Crain's for 2025
- Apex Raises $200 Million Series D Financing
- CCHR, a Mental Health Watchdog Organization, Hosts Weekly Events Educating Citizens on Important Mental Health Issues
- "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience
- New Slotozilla Project Explores What Happens When the World Goes Silent
- Long Beach City Council Adopts Fiscal Year 2026 Budget
- Lights, Camera, Action Underway as The 23rd Oakland International Film Festival Shines Spotlight on Justice, Healing & Community
- California: Governor Newsom announces appointments 9.11.25